Amgen said there is no link between its experimental weight loss drug, MariTide, and changes in bone density. The statement comes a day after that potential safety concern wiped off more than $12 ...

A blockbuster Amgen antibody that treats bone conditions is set to face its first biosimilar competition. The FDA on Tuesday approved two Sandoz drugs as interchangeable with and approved for all uses ...

Generic and biosimilar manufacturer Sandoz AG (OTC:SDZNY) (OTC:SDZXF) reached an agreement on Tuesday with Amgen Inc (NASDAQ:AMGN) to resolve all patent litigation related to its U.S. denosumab ...

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. Also Read: Jim Cramer Says Eli ...

Amgen (AMGN) stock is rising again after the biopharmaceutical producer addressed a recent data leak involving its weight loss drug’s impact on bone density. Earlier this week, AMGN shares plunged on ...

(RTTNews) - Amgen Inc. (AMGN) Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes in bone mineral density. Following the news, Amgen ...

In a blow to Amgen Inc., the Food and Drug Administration has said it wants more safety information about the company’s experimental bone-strength drug Prolia before granting marketing approval. The ...

Amgen on Wednesday said there is no link between its experimental weight loss drug, MariTide, and changes in bone density, a day after that potential safety concern wiped off more than $12 billion ...